Fate Therapeutics, Inc. (FATE)

Fate Therapeutics' stock has fluctuated in the past six months, with a recent price of $1.17 per share as of March 27, 2026, reflecting a 37.76% increase from the previous year. The 52-week trading range has been between $0.66 and $1.94. Recent news includes reports of new employee inducement awards, participation in the Leerink Partners 2026 Global Healthcare Conference, and financial results reports. Insider selling has exceeded insider buying in the past three months. Analyst consensus ratings suggest a "Hold" position, with an average twelve-month price target of $4.10.

As a clinical-stage biopharmaceutical company, traditional demand seasonality is not directly applicable to Fate Therapeutics' products. However, historical stock price data suggests some seasonality in stock performance, with April showing the highest probability of positive returns and March potentially being less ideal for investment.

Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. They utilize a proprietary iPSC product platform to create off-the-shelf NK cell and T-cell product candidates, aiming to overcome limitations of patient- or donor-sourced cell therapies. Their pipeline includes iPSC-derived CAR-targeted NK cell and T-cell product candidates such as FT819 and FT522.

Fate Therapeutics is headquartered in San Diego, California, where it operates a cGMP-compliant manufacturing facility. The company conducts clinical trials across North America and in select international sites. They have received regulatory clearance from the UK MHRA to proceed with clinical evaluation of FT819 in autoimmune diseases, with the first UK clinical site active and enrolling patients.

Fate Therapeutics has a reputation for scientific excellence, supported by its intellectual property portfolio. Positive clinical data for FT819 in autoimmune diseases and preclinical data for FT836 have reinforced its potential. The successful outpatient treatment of autoimmune patients using FT819 off-the-shelf CAR T-cells has been a significant milestone. However, market sentiment for cell therapy equities has cooled, impacting funding availability.

Fate Therapeutics has significant institutional ownership, with approximately 69.7% to 97.54% of shares held by institutional investors. Major institutional shareholders include Redmile Group, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual investors and the general public hold a smaller stake, while insiders hold approximately 5.51% to 13.00% of the stock.